A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...

Nonurinary sodium excretion in afebrile cirrhotic patients without diarrhea is approximately 10 mmol/day. [13] Patients with ascites on no diuretics commonly have renal sodium excretion of < 20 ...

Is your couch potato lifestyle killing your liver? Find out how liver disease, particularly NAFLD, is affecting millions and ...

The Phase III programme is expected to begin by the end of 2024 and is aiming to include a minimum of 1,800 patients.

Although substances like tobacco have reputations for being highly carcinogenic, or having the potential to cause cancer, ...

First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...

ETNB has a solid financial runway but faces risks from GLP-1 data and competition within the FGF21 space, making it a Hold ...

In 2024, The Food and Drug Administration in the US approved resmetirom, a liver-targeted thyroid hormone receptor ...

our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions ...

No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...

前言“慢加急性肝衰竭（ACLF）主题月评”是中国慢（加急）性肝衰竭联盟受《国际肝病》编辑部邀请，制作的ACLF相关学术月评专栏。本专栏每月以ACLF某一特定领域为主题展开，旨在普及ACLF的概念及意义、帮助读者快速了解有关领域的进展。希望本专栏对无论 ...

With an 8-week treatment duration, data from the lead-in cohort of non-cirrhotic patients showed a 97% SVR12 rate in efficacy evaluable patients. Two subjects (GT1b and GT2b) experienced ...